Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Hong, S. Y. Kim, B. H. Jeong, H. Y. Park, K. Jeon, O. J. Kwon, S. H. Lee, C. K. Kim, S. J. Shin, W. J. Koh (Seoul, Chungbuk, Republic Of Korea). Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Eur Respir J 2013; 42: Suppl. 57, 2731

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019 Retrospective observation of mycobacterium avium complex lung disease followed without treatment Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009 Treatment outcomes of macrolide-resistant mycobacterium avium complex lung disease Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006 Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005 The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016 Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020 Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019 Extrapulmonary mycobacterium bovis infection after one year of infliximab therapy Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008 Treatment failure in tuberculosis Source: Eur Respir J 2007; 29: 561-564 Year: 2007 Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017 Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009